Madagascar vs Panama: Average cost of multi drug-resistant tuberculosis treatment
Madagascar
532 constant 2022 US$
in 2024
Panama
572 constant 2022 US$
in 2024
Madagascar rank
77th
Panama rank
74th
Average cost of multi drug-resistant tuberculosis treatment over time
- Madagascar
- Panama
How they compare
Panama currently reports 572 constant 2022 US$ against 532 constant 2022 US$ in Madagascar, a difference of 40 constant 2022 US$.
That makes Panama's figure about 1.1 times Madagascar's.
Across all 5 years both countries report, Panama has been ahead every year.
Madagascar ranks 77th and Panama ranks 74th of 92 countries.
Panama has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Madagascar | Panama | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,413 constant 2022 US$ | 5,436 constant 2022 US$ | 4,024 constant 2022 US$ | Panama |
| 2020s | 516.33 constant 2022 US$ | 1,288 constant 2022 US$ | 771.67 constant 2022 US$ | Panama |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Madagascar or Panama?
- Panama, at 572 constant 2022 US$ against 532 constant 2022 US$ in Madagascar as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Madagascar and Panama?
- 40 constant 2022 US$, with Panama ahead.
- How many years of comparable data are there for Madagascar and Panama?
- 5 years are reported by both, from 2017 to 2024.
- How do Madagascar and Panama rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Madagascar ranks 77th and Panama ranks 74th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.